UPDATE 1-FDA approves Biogen drug for lead genetic cause of infant death

Dec 23 (Reuters) - The U.S. Food and Drug Administration on

Friday said it has approved Biogen Inc's drug to treat

spinal muscular atrophy, the leading genetic cause of death in

infants.

Read more